MedDataX Logo

A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

NCT ID: NCT00578825

Last Updated: 2013-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

340 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Acute Respiratory Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Severe acute respiratory syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lopinavir / Ritonavir plus Ribavirin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.

Exclusion Criteria

* Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Authority, Hong Kong

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wai Cho Yu, Dr

Role: PRINCIPAL_INVESTIGATOR

Department of Medicine & Geriatrics, Princess Margaret Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Health

Hong Kong, , China

Site Status

Kowloon Hospital

Hong Kong, , China

Site Status

Prince of Wales Hospital

Hong Kong, , China

Site Status

Princess Margaret Hospital

Hong Kong, , China

Site Status

Queen Mary Hospital

Hong Kong, , China

Site Status

The Chinese University of Hong Kong

Hong Kong, , China

Site Status

The University of Hong Kong

Hong Kong, , China

Site Status

Tuen Mun Hospital

Hong Kong, , China

Site Status

United Christian Hospital

Hong Kong, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wai Cho Yu, Dr

Role: CONTACT

Phone: (852) 2990 3737

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HARECCTR0500028

Identifier Type: -

Identifier Source: secondary_id

NTWC/CREC/349/05

Identifier Type: -

Identifier Source: secondary_id

KW/FR/04-009

Identifier Type: -

Identifier Source: org_study_id